NEW YORK (GenomeWeb News) – Foundation Medicine has filed with the US Securities and Exchange Commission to sell up to $150 million of its common stock in a public offering.

In a Form S-1 filed with the SEC on Thursday, the Cambridge, Mass.-based firm said the "purpose of this offering is to increase our financial flexibility," and proceeds will be used to accelerate its commercial operations and R&D, as well as to expand its technology infrastructure and technology platform, and to fund ongoing and new clinical trials.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: genes under positive selection in Plasmodium falciparum populations, genetic variation in Epstein-Barr viruses, and more.

Cancer clinical trial patients settle with Anil Potti and Duke University.

A trio of researchers is trying to raise money to sequence and analyze the genome of a cat with a suite of unusual traits.

Two Johns Hopkins researchers discuss the need for evidence-based data analysis.